Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

August 14, 2025 updated by: Janssen Research & Development, LLC

Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to assess the effects of administration of daratumumab when combined with VELCADE (bortezomib) and dexamethasone compared with bortezomib and dexamethasone alone, for participants with relapsed or refractory multiple myeloma.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This is an open-label (physicians and participants know the identity of the assigned treatment), randomized (the study medication is assigned by chance), multicenter, active-controlled study comparing daratumumab, VELCADE, and dexamethasone (DVd) with VELCADE and dexamethasone (Vd) in participants with relapsed or refractory multiple myeloma. Approximately 480 participants will be randomly assigned in a 1:1 ratio to receive either DVd or Vd. Randomization will be stratified by International Staging System (ISS), number of prior treatment programs (1 vs. 2 or 3 vs. >3), and prior VELCADE treatment ("no" vs. "yes"). Within each stratum, participants will be randomized to one of the treatment groups.The study will consist of a Screening Phase, a Treatment Phase, and a Follow-up Phase. Participants will be treated until disease progression, unacceptable toxicity, or other reasons to discontinue the study.

Study Type

Interventional

Enrollment (Actual)

498

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Australia
      • Adelaide, Australia
      • Concord, Australia
      • Fitzroy, Australia
      • Hobart, Australia
      • Melbourne, Australia
      • Nedlands, Australia
      • Woodville South, Australia
  • Brazil
      • Barretos, Brazil
      • Porto Alegre, Brazil
      • Salvador, Brazil
      • São Paulo, Brazil
  • Czechia
      • Brno, Czechia
      • Hradec Králové, Czechia
      • Ostrava-Poruba, Czechia
      • Prague, Czechia
  • Germany
      • Bamberg, Germany
      • Berlin, Germany
      • Düsseldorf, Germany
      • Freiburg im Breisgau, Germany
      • Göttingen, Germany
      • Hamburg, Germany
      • Mainz, Germany
      • München, Germany
      • Stuttgart, Germany
      • Tübingen, Germany
      • Ulm, Germany
      • Würzburg, Germany
  • Hungary
      • Budapest, Hungary
      • Debrecen, Hungary
      • Győr, Hungary
      • Pécs, Hungary
      • Veszprém, Hungary
  • Mexico
      • Huixquilucan, Mexico
      • Monterrey, Mexico
  • Netherlands
      • Alkmaar, Netherlands
      • Amersfoort, Netherlands
      • Dordrecht, Netherlands
      • Groningen, Netherlands
      • Leiden, Netherlands
      • Maastricht, Netherlands
      • Nijmegen, Netherlands
      • The Hague, Netherlands
  • Poland
      • Chorzów, Poland
      • Katowice, Poland
      • Krakow, Poland
      • Poznan, Poland
      • Warsaw, Poland
  • Russia
      • Krasnodar, Russia
      • Moscow, Russia
      • Nizhny Novgorod, Russia
      • Penza, Russia
      • Pyatigorsk, Russia
      • Ryazan, Russia
      • Samara, Russia
      • Sochi, Russia
      • Syktyvkar, Russia
  • South Korea
      • Busan, South Korea
      • Hwasun, South Korea
      • Seoul, South Korea
      • Suwon, South Korea
      • Ulsan, South Korea
  • Spain
      • Madrid, Spain
      • Salamanca, Spain
      • San Sebastián de los Reyes, Spain
      • Toledo, Spain
      • Valencia, Spain
  • Sweden
      • Linköping, Sweden
      • Luleå, Sweden
      • Lund, Sweden
      • Sundsvall, Sweden
      • Umeå, Sweden
      • Uppsala, Sweden
      • Västerås, Sweden
      • Örebro, Sweden
  • Turkey (Türkiye)
      • Ankara, Turkey (Türkiye)
      • Istanbul, Turkey (Türkiye)
      • Izmir, Turkey (Türkiye)
      • Kayseri, Turkey (Türkiye)
      • Kocaeli, Turkey (Türkiye)
      • Malatya, Turkey (Türkiye)
  • Ukraine
      • Cherkasy, Ukraine
      • Dnipro, Ukraine
      • Ivano-Frankivsk, Ukraine
      • Kiev, Ukraine
      • Lviv, Ukraine
      • Poltava, Ukraine
      • Vinnitsa, Ukraine
      • Zaporizhzhya, Ukraine
  • United States
    • Alabama
      • Birmingham, Alabama, United States
    • California
      • Los Angeles, California, United States
    • Connecticut
      • Stamford, Connecticut, United States
    • Florida
      • Jacksonville, Florida, United States
    • Georgia
      • Atlanta, Georgia, United States
    • Illinois
      • Niles, Illinois, United States
    • Kansas
      • Topeka, Kansas, United States
      • Westwood, Kansas, United States
    • Louisiana
      • Marrero, Louisiana, United States
    • Massachusetts
      • Boston, Massachusetts, United States
    • Michigan
      • Lansing, Michigan, United States
    • New York
      • New York, New York, United States
    • North Carolina
      • Chapel Hill, North Carolina, United States
    • Oregon
      • Portland, Oregon, United States
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States
    • Rhode Island
      • Providence, Rhode Island, United States
    • Washington
      • Seattle, Washington, United States

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Must have had documented multiple myeloma
  • Must have received at least 1 prior line of therapy for multiple myeloma
  • Must have had documented evidence of progressive disease as defined based on Investigator's determination of response of International Myeloma Working Group (IMWG) criteria on or after their last regimen
  • Must have an Eastern Cooperative Oncology Group Performance Status score of 0, 1, or 2
  • Must have achieved a response (partial response [PR] or better based on investigator's determination of response by the IMWG criteria) to at least 1 prior regimen in the past

Exclusion Criteria:

  • Has received daratumumab or other anti-CD38 therapies previously
  • Is refractory to VELCADE or another PI, like ixazomib and carfilzomib (had progression of disease while receiving VELCADE therapy or within 60 days of ending VELCADE therapy or another PI therapy, like ixazomib and carfilzomib
  • Is intolerant to VELCADE (ie, discontinued due to any adverse event while on VELCADE treatment)
  • Has received anti-myeloma treatment within 2 weeks or 5 pharmacokinetic half-lives of the treatment, whichever is longer, before the date of randomization. The only exception is emergency use of a short course of corticosteroids (equivalent of dexamethasone 40 milligram per day [mg/day] for a maximum of 4 days) before treatment. A list of anti-myeloma treatments with the corresponding pharmacokinetic half-lives is provided in the Site Investigational Product Procedures Manual (IPPM).
  • Has a history of malignancy (other than multiple myeloma) within 3 years before the date of randomization
  • Has any concurrent medical condition or disease (eg, active systemic infection) that is likely to interfere with study procedures

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Daratumumab+VELCADE+dexamethasone
Daratumumab, VELCADE and dexamethasone
Drug: Daratumumab
Daratumumab will be administered as an IV infusion or 16 mg/kg weekly for the first 3 cycles, on Day 1 of Cycles 4-9, and then every 4 weeks thereafter. As per protocol amendment-6 participants receiving treatment with daratumumab IV will have the option to switch to daratumumab SC 1800 mg on Day 1 of any cycle, at the discretion of the investigator.
Drug: VELCADE (Bortezomib)
VELCADE will be administered at a dose of 1.3 mg/m2 subcutaneously (SC) on Days 1, 4, 8 and 11 of each 21-day cycle. Eight VELCADE treatment cycles are to be administered.
Other Names:
  • VELCADE
Drug: Dexamethasone
Dexamethasone will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 VELCADE treatment cycles.
Active Comparator: VELCADE+dexamethasone
VELCADE and dexamethasone.
Drug: VELCADE (Bortezomib)
VELCADE will be administered at a dose of 1.3 mg/m2 subcutaneously (SC) on Days 1, 4, 8 and 11 of each 21-day cycle. Eight VELCADE treatment cycles are to be administered.
Other Names:
  • VELCADE
Drug: Dexamethasone
Dexamethasone will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 VELCADE treatment cycles.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Progression-free Survival (PFS)
Time Frame: From the date of randomization to either progressive disease or death, whichever occurred first (approximately 1 year 4 months)
PFS was defined as duration from date of randomization to either progressive disease (PD)/death, whichever occurred first. PD was defined as meeting any one of following criteria: Increase of greater than equal to (>=)25 percent (%) in level of serum M-protein from lowest response value and absolute increase must be >=0.5 gram per deciliter (g/dL); Increase of >=25% in 24-hour urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be >=200 mg/24hours; Only in participants without measurable serum and urine M-protein levels: increase of >=25% in difference between involved and uninvolved FLC levels from lowest response value and absolute increase must be >10 mg/dL; Definite increase in size of existing bone lesions or soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium >11.5 mg/dL) that can be attributed solely to PC proliferative disorder.
From the date of randomization to either progressive disease or death, whichever occurred first (approximately 1 year 4 months)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to Disease Progression (TTP)
Time Frame: From the date of randomization to the date of first documented evidence of progression or death due to PD whichever occurred first (approximately 6 years 9 months)
TTP was defined as time from date of randomization to date of first documented evidence of progressive disease (PD). PD was defined as meeting any one of following criteria: Increase of >=25% in level of serum M-protein from lowest response value and absolute increase must be >=0.5 g/dL; Increase of >=25% in 24-hour urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be >=200 mg/24hours; Only in participants without measurable serum and urine M-protein levels: increase of >=25% in difference between involved and uninvolved free light chain (FLC) levels from lowest response value and absolute increase must be >10 milligram per deciliter (mg/dL); Definite increase in size of existing bone lesions or soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium >11.5 mg/dL) that can be attributed solely to Plasma Cell (PC) proliferative disorder.
From the date of randomization to the date of first documented evidence of progression or death due to PD whichever occurred first (approximately 6 years 9 months)
Percentage of Participants With a Very Good Partial Response (VGPR) or Better
Time Frame: Up to disease progression (approximately 6 years 9 months)
Response rate of VGPR or better was defined as the percentage of participants who achieved VGPR and CR (including sCR) according to the IMWG criteria during or after the study treatment. IMWG criteria for VGPR: Serum and urine M-component detectable by immunofixation but not on electrophoresis, or >=90% reduction in serum M-protein plus urine M-protein <100 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of >90% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria, in addition to the above criteria, if present at baseline, a >=50% reduction in the size of soft tissue plasmacytomas is also required; CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and <5% PCs in bone marrow; sCR: CR and normal FLC ratio, absence of clonal PCs by immunohistochemistry, immunofluorescence or 2 to 4 color flow cytometry.
Up to disease progression (approximately 6 years 9 months)
Overall Response Rate (ORR)
Time Frame: Up to disease progression (approximately 6 years 9 months)
The Overall response rate was defined as the percentage of participants who achieved stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) according to the International Myeloma Working Group (IMWG) criteria, during the study or during follow up. IMWG criteria for PR: >=50% reduction of serum M-protein and reduction in 24 hour urinary M-protein by >=90% or to <200 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of >=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria, in addition to the above criteria, if present at baseline, a >=50% reduction in the size of soft tissue plasmacytomas is also required.
Up to disease progression (approximately 6 years 9 months)
Percentage of Participants With Negative Minimal Residual Disease (MRD)
Time Frame: Up to disease progression (approximately 6 years 9 months)
The Minimal Residual Disease negativity rate was defined as the percentage of participants who had negative MRD assessment at any timepoint after the first dose of study drugs by evaluation of bone marrow aspirates or whole blood. MRD was assessed in participants who achieved complete response or stringent complete response (CR/sCR). IMWG criteria for CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and <5% PCs in bone marrow; sCR: CR plus normal FLC ratio, absence of clonal PCs by immunohistochemistry, immunofluorescence or 2 to 4 color flow cytometry.
Up to disease progression (approximately 6 years 9 months)
Overall Survival (OS)
Time Frame: Up to 6 years 9 months
Overall Survival was measured from the date of randomization to the date of the participant's death.
Up to 6 years 9 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Janssen Research & Development, LLC

Investigators

  • Study Director: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 15, 2014

Primary Completion (Actual)

January 11, 2016

Study Completion (Actual)

January 10, 2024

Study Registration Dates

First Submitted

May 1, 2014

First Submitted That Met QC Criteria

May 8, 2014

First Posted (Estimated)

May 12, 2014

Study Record Updates

Last Update Posted (Estimated)

August 29, 2025

Last Update Submitted That Met QC Criteria

August 14, 2025

Last Verified

August 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CR103995
  • 2014-000255-85 (EudraCT Number)
  • 54767414MMY3004 (Other Identifier: Janssen Research & Development, LLC)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multiple Myeloma

Clinical Trials on Daratumumab

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kyrgyzstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe